Opendata, web and dolomites

LDMBI

Low dose Molecular Breast Imaging for improved cancer detection in dense breast tissue.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "LDMBI" data sheet

The following table provides information about the project.

Coordinator
KROMEK LIMITED 

Organization address
address: THOMAS WRIGHT WAY NETPARK
city: SEDGEFIELD DURHAM
postcode: TS21 3FD
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.kromek.com/index.php/horizon-2020
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KROMEK LIMITED UK (SEDGEFIELD DURHAM) coordinator 50˙000.00

Map

 Project objective

The 50% of women with dense breast tissue who are currently screened for breast cancer by mammography have large numbers of cancers missed, and non-cancerous features erroneously diagnosed, due to the difficulty of a mammogram distinguishing tumours from dense breast tissue. In dense breasts, around 1 in 2 cancers is missed by mammography. Molecular Breast Imaging has much higher sensitivity (a better cancer detection rate) and specificity (fewer false alarms) than mammography, particularly for dense breasts. Its use as a screening technology is currently restricted due to its high radiation dose and inability to guide a biopsy. This feasibility study will investigate the technical, economic and regulatory viability of Kromek’s technology to being adopted in optimised diagnosis pathways. Kromek currently supplies detectors into the MBI market, and have a number of innovative platform technologies to add to the current offering to create a system to address these barriers to adoption. Work in this Phase 1 study will identify the dose vs cancer detection balance, to guide the application of the technologies to the market needs. We predict sales in the EU and USA of 147 million Euros in the first five years after commercialisation, which will help address the approximately 110 thousand women in Europe whose cancers in dense breasts are currently missed by mammography.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LDMBI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LDMBI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More